News | February 17, 2023
Biocon Q3 FY23 revenue up 36%
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
91% of cloud leaders expect their cloud capabilities to be largely centralized within the next 2 years and 64% of cloud leaders have realized cybersecurity cost savings by migrating to cloud
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Zidavi is recommended by the Infectious Disease Society of America
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Krsnaa Diagnostics Limited has operationalized one diagnostics center at district hospital Male Akbarpur, Kanpur Dehat, Uttar Pradesh.
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
Subscribe To Our Newsletter & Stay Updated
